• Stephen Squinto

    Chairman of the Board

    Stephen Squinto is an Executive Partner with OrbiMed. He was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head of Research and Development. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and Louisiana State University Medical Schools. Dr. Squinto obtained his PhD in biochemistry and biophysics from Loyola University in Chicago. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.

  • Adi Mor

    Chief Executive Officer & Co-Founder

    Adi Mor co-founded Chemomab in 2011 and is serving as the company’s CEO since. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.

  • Alan Moses

    Director

    Alan Moses, spent 14 years at Novo Nordisk, held multiple roles and rising to the position of Senior Vice President and Global Chief Medical Officer. Dr. Moses was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT and served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston and was appointed Professor of Medicine at Harvard Medical School. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

  • Claude Nicaise

    Director

    Claude Nicaise is the owner of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies.

    Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development, Vice-President of Worldwide Regulatory Science and Strategy, and leadership positions in Oncology, Infectious Disease, and Neuroscience development.  Dr. Nicaise is a board member in several public and private companies and received his medical degree from the Université Libre de Bruxelles in Belgium.

  • Joel Maryles

    Director

    Joel Maryles has held numerous senior positions in the financial sector over the past three decades. Mr. Maryles was a Partner at OurCrowd from 2015 to 2018. From 2007 to 2012, Mr. Maryles was a portfolio manager of T-Cubed Investments LP, an equity hedge fund that he founded. From 1996 to 2006, he was a Managing Director at Citigroup Investment Banking where, in addition to his role as a senior technology banker, he founded and managed the Israeli investment banking operations for Citigroup/Salomon Smith Barney. Previously, Mr. Maryles held various senior positions at Furman Selz, a U.S.-based investment bank, including Managing Director focused on Israeli technology and healthcare transactions and was an Investment Officer at First Chicago Investment Advisors. Mr. Maryles holds a B.Sc. degree in engineering from the University of Illinois and an M.B.A. from the University of Chicago.

  • Neil Cohen

    Director

    Neil Cohen served as interim CEO of Anchiano Therapeutics (NASDAQ: ANCN) from October 2020 until its merger with Chemomab in March 2021. He has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public offerings. He is a venture partner at SKY, an Israeli middle-market private equity firm, at Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at the Rothschild Bioscience Unit of N M Rothschild & Sons Limited in London. Mr. Cohen received a B.A. and M.A., with first class honors, from Oxford University.

  • Nissim Darvish

    Director

    Nissim Darvish is a Venture Partner at OrbiMed Israel. Dr. Darvish is a veteran of the life science industry, with fifteen over 20 years of experience covering biotech, medical technology development, corporate leadership and investment management. Dr. Darvish spent 8 years with Pitango, where he was a General Partner managing life sciences investments. Previously, Dr. Darvish was the founder and CEO of Impulse Dynamics, which he led for 6 years, culminating in a $250 million realization event. Dr. Darvish obtained his MD and PhD in biophysics and physiology from the Technion in Israel and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received 8 distinguished prizes and awards.